TKG Therapeutics is a pharmaceutical company that focuses on developing nucleic acid drugs using new-age medical technology.
TKG Therapeutics has raised $1.0M in total funding. The most recent round was Seed. The last funding was announced in January 2024.
TKG Therapeutics's investors include UntroD Capital, NEDO, Mitsubishi Gas Chemical.
TKG Therapeutics is headquartered in Tokyo, Japan.
TKG Therapeutics is a pharmaceutical company that focuses on developing nucleic acid drugs using new-age medical technology.
TKG Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TKG Therapeutics — Funding & Investors." VCBacked, January 31, 2024, https://www.vcbacked.co/company/tkg-therapeutics. Accessed October 5, 2026.
VCBacked. (2024). TKG Therapeutics — Funding & Investors. Retrieved October 5, 2026, from https://www.vcbacked.co/company/tkg-therapeutics
{{cite web |title=TKG Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tkg-therapeutics |website=VCBacked |access-date=October 5, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated